Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 126

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 126
---
 |

The research revenues earned by us were $43,177 for the nine months ended September 30, 2024, as compared to $82,974 for the nine months ended September 30, 2023. Our research revenues for the nine months ended September 30, 2023 consist entirely of projected research revenues from the Australian Tax Authority for research activities conducted in Australia at $82,974, compared to $29,821 for the nine months ended September 30, 2024. For the nine months ended September 30, 2024, we began to recognize research revenues related to initial funding earned from the new USAMMDA contract we were awarded in July 2024 to facilitate commercial validation of a new bottle and replacement blister packaging of Arakoda. Operating Expenses

|                                     | Consolidated Statements of Operations Data: | Nine Months Ended 
 September 30,     |      2024 |     |   |      2023 |     |   |  $ Change |     |     | % Change |   |
|:------------------------------------|:--------------------------------------------|:------------------|----------:|:----|:--|----------:|:----|:--|----------:|:----|:----|---------:|:--|
| Research and Development            |                                             | $                 | 4,372,571 |     | $ |   591,569 |     | $ | 3,781,002 |     |     |   639.15 | % |
| General and Administrative Expenses |                                             |                   | 3,419,747 |     |   | 2,551,426 |     |   |   868,321 |     |     |    34.03 |   |
| Total Operating Expenses            |                                             | $                 | 7,792,318 |     | $ | 3,142,995 |     | $ | 4,649,323 |     |     |   147.93 | % |

Research and Development Research and development costs increased during the nine months ended September 30, 2024 when compared to the nine months ended September 30, 2023. Research and development costs incurred during the nine months ended September 30, 2023 consisted of initiation costs related to our Phase IIB COVID-19 clinical trial, which was later suspended in the fourth quarter of 2023. Direct COVID-19-related trial costs represent less than 1% of the total costs for